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ABSTRACT
Objectives: To determine whether nalmefene
combined with psychosocial support is cost-effective
compared with psychosocial support alone for
reducing alcohol consumption in alcohol-dependent
patients with high/very high drinking risk levels (DRLs)
as defined by the WHO, and to evaluate the public
health benefit of reducing harmful alcohol-attributable
diseases, injuries and deaths.
Design: Decision modelling using Markov chains
compared costs and effects over 5 years.
Setting: The analysis was from the perspective of the
National Health Service (NHS) in England and Wales.
Participants: The model considered the licensed
population for nalmefene, specifically adults with both
alcohol dependence and high/very high DRLs, who do
not require immediate detoxification and who continue
to have high/very high DRLs after initial assessment.
Data sources: We modelled treatment effect using
data from three clinical trials for nalmefene (ESENSE 1
(NCT00811720), ESENSE 2 (NCT00812461) and
SENSE (NCT00811941)). Baseline characteristics of the
model population, treatment resource utilisation and
utilities were from these trials. We estimated the
number of alcohol-attributable events occurring at
different levels of alcohol consumption based on
published epidemiological risk-relation studies. Health-
related costs were from UK sources.
Main outcome measures: We measured incremental
cost per quality-adjusted life year (QALY) gained and
number of alcohol-attributable harmful events avoided.
Results: Nalmefene in combination with psychosocial
support had an incremental cost-effectiveness ratio
(ICER) of £5204 per QALY gained, and was therefore
cost-effective at the £20 000 per QALY gained decision
threshold. Sensitivity analyses showed that the
conclusion was robust. Nalmefene plus psychosocial
support led to the avoidance of 7179 alcohol-
attributable diseases/injuries and 309 deaths
per 100 000 patients compared to psychosocial support
alone over the course of 5 years.
Conclusions: Nalmefene can be seen as a cost-
effective treatment for alcohol dependence, with
substantial public health benefits.
Strengths and limitations of this study
▪ This cost-effectiveness analysis employed an
innovative approach towards modelling the treat-
ment of alcohol dependence using WHO drinking
risk levels and abstinence as health states.
▪ The analysis also used an innovative approach
for modelling the incidence of alcohol-attribut-
able harmful events.
▪ This analysis is based on 1-year clinical trial data
assessing nalmefene, extended to a time horizon
of 5 years as appropriate for a chronic disease
using data from the literature and clinical
experts’ advice. Simplifications of certain model-
ling features when extrapolating patients’ trajec-
tories after the trial time horizon represent
limitations of the decision model.
▪ The exploratory ‘no treatment’ arm used to
assess the public health benefit of patients
beginning treatment for alcohol dependence may
not be an accurate representation of the natural
evolution of the disease when untreated. The
results from this analysis should not be taken at
face value but seen as a broad estimation of the
benefit of patients entering treatment for alcohol
dependence.
▪ The generalisability of this study to the UK popu-
lation may be suboptimal, owing to the fact that
the nalmefene clinical trials were multinational.
Furthermore, the use of quality-adjusted life years
(QALYs) derived from these trials may not have
fully captured the effectiveness of nalmefene.
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Trial registration numbers: This cost-effectiveness analysis was
developed based on data from three randomised clinical trials:
ESENSE 1 (NCT00811720), ESENSE 2 (NCT00812461) and SENSE
(NCT00811941).
INTRODUCTION
The physical, psychological and social harms of alcohol
consumption represent an important public health
problem and impose substantial costs on society.1 2
Alcohol consumption is associated with an increased risk
of disability and mortality, due to the development of
diseases linked with alcohol consumption including liver
cirrhosis, certain cancers and cardiovascular diseases
and alcohol-related injuries such as falls and automobile
accidents.3 4 Given that most dose–response curves for
alcohol consumption on disease and injury outcomes
are exponential, heavy drinking, both episodic and
chronic, plays a major role in creating this disease
burden.5 6 In Europe it has been estimated that more
than two-thirds of overall premature adult mortality
(ages 15–64) is due to heavy drinking.7 As alcohol use
disorders, especially alcohol dependence, are closely
linked to heavy drinking occasions, the majority of pre-
mature mortalities in the aforementioned study were a
result of alcohol-attributable disorders.7 High levels of
alcohol consumption can also prove economically costly
through treatment costs, productivity losses and losses
due to alcohol-related crime and accidents.2 8
While historically the National Institute for Health
and Care Excellence (NICE) has recommended inter-
ventions to promote abstinence from alcohol, harm
reduction by lowering alcohol consumption is now
recognised as a valid objective in the treatment of
alcohol dependence.8 9 The European Medicines
Agency (EMA) has outlined two types of clinical trial for
alcohol dependence treatments: ‘relapse prevention’
trials and ‘harm reduction’ trials.10 ‘Relapse prevention’
trials are suitable for agents such as acamprosate and
naltrexone, of which the purpose is to promote sus-
tained abstinence after successful detoxiﬁcation. ‘Harm
reduction’ trials are suitable for agents aiming to lower
alcohol consumption levels in patients who are non-
abstinent at trial randomisation.
Nalmefene is the ﬁrst pharmacological treatment
licensed in the European Union (EU) to achieve reduc-
tion of alcohol consumption.11 It is an opioid system
modulator with a distinct μ, δ and κ receptor proﬁle,
and by modulating the effect of alcohol on the cortico-
mesolimbic system it is thought to reduce the reinfor-
cing effects of alcohol, thereby helping patients to
reduce their level of consumption.12 13 Nalmefene is
indicated in the EU, in conjunction with psychosocial
support, for alcohol-dependent adult patients who are
both alcohol-dependent and who also have a high/very
high drinking risk level (DRL) as deﬁned by the WHO
(table 1). In addition, it is indicated only for patients
without physical withdrawal symptoms and those who do
not require immediate detoxiﬁcation. It should be
initiated only in patients who continue to have a high/
very high DRL 2 weeks after initial assessment, in
line with the patient population included in three
phase III clinical trials of nalmefene: ESENSE 1
(NCT00811720), ESENSE 2 (NCT00812461) and SENSE
(NCT00811941).14 15 These trials demonstrated the clin-
ical efﬁcacy of nalmefene in its licensed population in
terms of reducing the number of heavy drinking days
(HDDs) per month and daily total alcohol consumption
(TAC). Based on dosing used in these trials, nalmefene
should be taken on an as-needed basis each day that the
patient perceives a risk of drinking alcohol, with a
maximum dose of one tablet per day.11
The relevance of reducing alcohol consumption, as
opposed to promoting complete abstinence, has been a
key focus of discussions in the UK surrounding the pos-
sible introduction of minimum pricing of alcohol. The
principle behind this proposal is that increasing the cost
of purchasing alcohol may reduce the level of alcohol
consumption in harmful drinkers, which may in turn
have a meaningful impact on reducing alcohol-related
harms and burden.17 In Scotland, research using the
Shefﬁeld Alcohol Policy Model was used to quantify the
expected beneﬁt of introducing a minimum price of 50
pence per unit, reporting an expected fall in alcohol-
related deaths by 60 in the ﬁrst year and a ﬁnancial
saving from harm reduction of £942 million over 10
years.18 19 Nalmefene is currently reimbursed without
restriction in the UK in Scotland and in Wales for its
approved indication.20 21 Nalmefene has also received a
preliminary recommendation from the NICE Appraisal
Committee within its marketing authorisation and
without restriction.22 The ﬁnal NICE guidance will be
published in November 2014.23
This article reports on a Markov model that evaluated,
as a primary objective, whether nalmefene used in com-
bination with psychosocial support was cost-effective
compared with psychosocial support alone in alcohol-
dependent patients with a high/very high DRL, in line
with the indication for nalmefene.11 The perspective was
that of the National Health Service (NHS) in England
and Wales. As a secondary objective, to evaluate the
public health beneﬁt of patients entering treatment for
alcohol dependence, this model assessed the avoidance
of alcohol-attributable diseases, injuries and deaths with
nalmefene plus psychosocial support versus psychosocial
support alone and versus a ‘no treatment’ arm of con-
tinuous high-risk drinking patients.
METHODS
Overview
We developed a Markov model to estimate the direct
medical costs and changes in quality-adjusted life years
(QALYs) attributable to alcohol treatment and
alcohol-attributable harmful events from the perspective
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of the NHS in England and Wales. A secondary aim was
to assess the public health beneﬁt of treatment for
alcohol dependence in terms of the number of
alcohol-attributable events avoided. The economic ana-
lysis was conducted in Microsoft Excel 2010. A Markov
model was considered appropriate for modelling the
effects of reducing alcohol consumption, since the
natural history of the condition could be described as
discrete health states, deﬁned based on DRLs (table 1).
The 5-year time horizon of the model was divided into
two phases: a short-term phase lasting 1 year and a sub-
sequent long-term phase spanning years 2–5. We evalu-
ated the primary health effects of treatment using
efﬁcacy data from the three nalmefene clinical trials to
inform the level of reduction of alcohol consumption in
alcohol-dependent patients for the ﬁrst year.14 15
Patient-level data from the three nalmefene trials were
pooled and computed for their inclusion in the model
using the statistical software SAS V.9.2. The clinical effect
for the short-term phase closely modelled the drinking
patterns observed in the clinical trials, while drinking
patterns for the long-term phase were derived by
extrapolating results from these trials. We calculated the
secondary effects of treatment on alcohol-attributable
harmful events using evidence derived from the pub-
lished literature.
The model had two intervention arms for the cost-
effectiveness assessment: nalmefene plus psychosocial
support and psychosocial support alone. Psychosocial
support was considered the most appropriate compara-
tor for nalmefene since NICE guidelines recommend
that psychosocial intervention is the preferred treatment
option in alcohol-dependent patients for whom reduc-
tion of alcohol consumption is a medically relevant treat-
ment approach, but who do not require immediate
detoxiﬁcation.8 In addition, clinical data for the use of
naltrexone and acamprosate in these patients are
limited, therefore NICE recommends these treatments
only for patients who fail psychosocial intervention
alone.8 In the cost-effectiveness analysis, we reported
treatment effect with nalmefene plus psychosocial
support versus psychosocial support alone in terms of
QALYs, a common health measure capturing changes in
morbidity and mortality.
A third arm of continuous high-risk drinkers was
included as a ‘no treatment’ arm for an additional explora-
tory analysis to assess the public health beneﬁt of reducing
the number of alcohol-attributable harmful events on
entering treatment for alcohol dependence. These were
patients deemed eligible for treatment with nalmefene,
having high or very high DRLs at baseline and randomisa-
tion. This arm extended the distribution of patients across
DRLs recorded in the prebaseline period of the nalme-
fene clinical trials over the model time horizon.
Patient population
The model population was based on a subsample of
patients from the three nalmefene clinical trials: patients
who continued to have a high/very high DRL during
the 2-week period between baseline and randomisation
(table 2). These patients represent the population that
beneﬁts most from treatment with nalmefene, and thus
constitute the licensed population for nalmefene.11
Treatment efficacy
Treatment efﬁcacy was modelled primarily by changes in
the level of alcohol consumption, reﬂected as differ-
ences between treatment arms in the probabilities of
transitioning between DRL health states. We modelled
the efﬁcacy of nalmefene plus psychosocial support
versus psychosocial support alone using data from the
three nalmefene clinical trials: ESENSE 1 and ESENSE 2
assessed treatment efﬁcacy for 6 months,14 while the
SENSE study assessed efﬁcacy for 1 year.15 All three trials
compared nalmefene plus BRENDA versus placebo plus
BRENDA. The BRENDA approach is a form of psycho-
social support provided by clinicians to manage chronic
behavioural problems in primary and specialist care and
was developed speciﬁcally for use with medication to
promote adherence to treatment.24
Key efﬁcacy end points in all three studies were the
reduction in number of HDDs per month and daily
TAC. Pooled data from these trials were used in our
model (table 3). We used the nalmefene plus BRENDA
Table 2 Patient population characteristics from ESENSE
1, ESENSE 2 and SENSE trials (high/very high DRL at
baseline and randomisation)14 15
Characteristic Pooled estimates
Age (mean years) 48
Gender (% men) 69
DRL (%)
Very high risk 58
High risk 42
DRL, Drinking risk level.
Table 1 Categorical levels for average volume of pure
alcohol per day for women and men16
Category
Average volume
of pure alcohol
per day for
women (g)
Average
volume of pure
alcohol per day
for men (g)
WHO-criteria for risk of consumption on a single drinking
day in relation to acute problems
Low risk 0–20 0–40
Medium risk 21–40 41–60
High risk 41–60 61–100
Very high risk >61 >101
WHO-criteria for risk of consumption on a single drinking
day in relation to chronic harm
I (low risk) 0–20 0–40
II (medium risk) 21–40 41–60
III (high risk) ≥41 ≥61
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arms from the trials to model the nalmefene plus psy-
chosocial support cohort, and the placebo plus
BRENDA arms to model the psychosocial support
cohort. Pooled data from the three trials have been used
to derive monthly transition probabilities between the
drinking level health states in the ﬁrst year of the model,
as well as treatment discontinuation. Data from SENSE
were used to inform transition probabilities in the long-
term phase of the model (years 2–5).
The third ‘no treatment’ arm of continuous high-risk
drinkers was modelled using the monthly prebaseline
distributions and drinking characteristics of nalmefene’s
licensed population from the nalmefene clinical trials,
reproduced for the whole model time horizon. TAC and
HDDs taken from the monthly prebaseline period were
used to represent the drinking level and pattern for
these patients each month in the model. For the ‘no
treatment’ population, the mean number of HDDs was
21.8 and the mean daily TAC was 104 g/day for each
month (table 4).
As a secondary measure, efﬁcacy was further assessed by
modelling the secondary effects of alcohol consumption
on the incidence of alcohol-attributable harmful events.
Model structure
We applied a 1-month cycle length in the model’s within-
trial short-term phase (year 1), as aligned with the dur-
ation of patient follow-up in the nalmefene clinical trials
and the recommended frequency of follow-up with a clin-
ician in the summary of product characteristics for nal-
mefene.14 15 25 During the short-term phase, we
modelled ﬁve key health states in line with DRL categor-
ies as deﬁned by the WHO16: very high, high, medium
and low risk of drinking and abstinence (ﬁgure 1 and
table 1). In the long-term phase (years 2–5), we set the
cycle length to 1 year based on the availability of reliable
clinical data particularly with regard to the maintenance
of effect and probability of relapse to heavy drinking. A
long cycle length necessitating fewer cycles in the long-
term phase also limited the uncertainty from extrapolat-
ing outcomes from the nalmefene clinical trials beyond
the duration of the trials. The clinical data informed the
three health states used for the long-term phase of the
model (years 2–5): controlled drinking (including low
DRL and abstinence), medium risk drinking, and high or
very high-risk drinking (ﬁgure 1).
Throughout the 5-year time horizon, in addition to
the drinking level health states, we included health
states for serious and temporary alcohol-attributable
diseases and injuries. These represent alcohol-
attributable diseases and injuries known to incur a sig-
niﬁcant cost to the healthcare system, that had strong
evidence for their association with alcohol consumption,
and that occurred during the 5-year time horizon of the
model. We also included a death state. Temporary
harmful events were modelled as a tunnel state lasting
1 month, while serious harmful events involved the
patient moving to a permanent postevent state outside
of the drinking health states. The use of a 5-year time
horizon was considered an appropriate time to capture
relevant costs and effects pertaining to the treatments
being compared without reaching unacceptable uncer-
tainty in terms of patients’ long-term drinking behav-
iour, treatment needs and development of chronic
diseases from long-term alcohol consumption.
Patients entered the short-term phase of the model at
either high or very high DRL. At each cycle patients had
the chance of transitioning between any of the ﬁve
short-term DRL states, or remaining in the health state
they were currently in (ﬁgure 1). At the end of the
short-term phase, patients in the low DRL state or abstin-
ent after responding to treatment transitioned to the
controlled drinking health state where they did not
receive further treatment (ﬁgure 1). This is aligned with
the fact that clinical data for the use of nalmefene
under randomised controlled conditions are available
for a period of 12 months, and that caution is advised in
the drug license if nalmefene is prescribed for more
than 1 year.25 We considered patients in the medium
DRL state after the ﬁrst 12 months to have partially
responded to treatment. We assumed that these patients
would continue in the same treatment arm in the long-
term medium DRL state, given the risks of acute and
chronic harms at this level of drinking. Patients in this
state had the possibility of transitioning each cycle to
either the long-term high/very high DRL state or the
Table 3 Adjusted change from baseline in monthly HDDs and TAC (FAS, OC, MMRM)—ESENSE 1, ESENSE 2 and
SENSE (high/very high DRL at baseline and randomisation)14 15
Number of participants
at baseline
End
point
Mean difference to
placebo in the change
from baseline 95% CI p Value
Nalmefene
+PS
Placebo
+PS
Pooled studies (month 6)
(ESENSE 1 and 2, SENSE)
460 364 HDD −3.01 days/month −4.36 to −1.66 <0.0001
TAC −14.22 g/day −19.96 to −8.47 <0.0001
SENSE (month 13) 141 42 HDD −3.60 HDDs/month −6.52 to −0.67 0.0164
TAC −17.31 g/day −30.87 to −3.76 0.0129
DRL, drinking risk level; FAS, full analysis set; HDD, heavy drinking day; MMRM, mixed model repeated measures; OC, cbserved cases; PS,
psychosocial support; TAC, total alcohol consumption.
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Table 4 Proportion of patients starting in each health state, nalmefene intake and alcohol consumption parameters
associated with the short-term and long-term DRL health states14 15
Item
Initial proportion
of patients at
model start (%)
Mean alcohol
consumption
(g/day)
Mean alcohol
consumption per
HDD (g/day)
Mean
number of
HDDs per
month
Mean
nalmefene
intake per
month*
Short-term DRL health states
Males
Very high risk 42 134 153 25 20.5
High risk 58 78 113 19 19.9
Medium risk 0 50 107 10 16.5
Low risk 0 21 81 3 13.9
Abstinence 0 – – – 8.8
Females
Very high risk 42 94 108 24 19.1
High risk 58 50 74 19 18.9
Medium risk 0 29 67 9 16.5
Low risk 0 11 50 3 14.8
Abstinence 0 – – – 7.7
Long-term DRL health states
Males
Very high and high risk – 104 132 22 NA
Medium risk – 50 107 10 16.5
Controlled drinking – 16 65 3 NA
Females
Very high and high risk – 75 93 22 NA
Medium risk – 29 67 9 16.5
Controlled drinking – 9 40 2 NA
Mean estimates or counts of patients based on observed case data from ESENSE 1, ESENSE 2 and SENSE were pooled for the first
6 months to inform the model DRL health state transition probabilities and utility values for the DRL health states. Following the first 6 months,
data from SENSE were used up to 12 months, after which data from this study were extrapolated to the 5-year model time horizon.
*Pooling the three nalmefene trials, nalmefene intake was 35% of the days over one year when dividing the number of days of intake by the
full study period; and it was 56% of the days over 1 year when dividing the number of days of intake per individual patient by the number of
days the patient was in the trial (until dropout or end of study).
DRL, drinking risk level; HDD, heavy drinking day.
Figure 1 Summary of the health states and events incorporated in the short-term and long-term phases of the model. *At each
cycle, patients in the controlled drinking state could relapse into the drinking state they were in at the start of the model (high
drinking risk levels (DRL) or very high DRL states in the short-term phase of the model), and hence to the original treatment they
were successful with.
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controlled drinking state, or staying in the medium DRL
state (ﬁgure 1). We considered patients in the high and
very high DRL states at the end of the ﬁrst 12 months as
having not responded to treatment. These patients
therefore transitioned to the long-term high/very high
DRL state without receiving further treatment and were
modelled as continuous drinkers for the remainder of
the model’s time horizon. It was a conservative assump-
tion to suppose that patients would not begin alternative
treatment.
Each year, patients in the controlled drinking state of
the long-term phase could relapse into their original
drinking state (high or very high DRL) in the short-term
phase of the model, receiving a second round of treat-
ment using the strategy that was initially successful at
controlling their alcohol consumption; this was consid-
ered a clinically relevant supposition. Patients who
relapsed returned to the beginning of the model’s short-
term phase, both in terms of DRL and state transition
probabilities. Patients not experiencing a relapse
remained in the controlled drinking state for the
remainder of the model’s time horizon (ﬁgure 1).
Throughout the model time horizon, at each cycle all
patients had a chance of experiencing a harmful event,
including death, at rates speciﬁc to each health state.
Patients could move from any of the health states to the
death state, either due to alcohol-attributable harmful
events or all-cause mortality (ﬁgure 1).
As seen during clinical trials for nalmefene, dropouts
from treatment could occur from nalmefene-related
adverse events (mainly nausea, headache, dizziness or
insomnia) or due to other reasons (mainly withdrawal of
consent or protocol violation).14 15 After dropping out
due to a nalmefene-related adverse event, patients stayed
in the nalmefene plus psychosocial support cohort but
were subject to transition probabilities from the psycho-
social support alone arm. We assumed that these
patients would be willing to continue receiving psycho-
social support, but not nalmefene due to excessive dis-
comfort from the adverse events. Patients in either
treatment arm dropping out for reasons other than
adverse events transitioned to a ‘continuous high risk
drinking’ state, where they remained permanently at a
high or very high DRL. This was deemed to be a conser-
vative assumption related to treatment failure.
Model parameters
Four categories of parameters were included in the
model: (1) health state transition probabilities for DRLs,
based on the three nalmefene clinical trials for the
short-term phase of the model, and based on extrapola-
tion from the nalmefene trials and from complementary
sources and assumptions for the long-term phase; (2)
incidence of alcohol-attributable diseases, injuries and
deaths based on published epidemiological risk-relation
studies; (3) utilities taken from the nalmefene clinical
trials for drinking health states for the base-case, from a
UK naturalistic study for the sensitivity analysis, and
from UK published sources for alcohol-attributable dis-
eases and injuries; and (4) resource use and costs
related to alcohol-dependence treatment based on the
nalmefene clinical trials, and on UK sources for the
treatment of alcohol-attributable diseases and injuries.
Health state transition probabilities for DRLs
The initial proportions of patients in the high and very
high DRL health states at the start of the model and the
monthly probabilities of transitioning between the ﬁve
health states in the short-term phase of the model
(including treatment dropout) were calculated as the
pooled proportions at randomisation and in each health
state each month, respectively, in the nalmefene clinical
trials. The monthly transition probabilities were based
on the count of patients (observed cases) each month
for compared treatment cohorts (table 4; see online sup-
plementary table A).
For the long-term phase of the model, we derived the
yearly health state transition probabilities for patients in
the medium DRL health state using the average transi-
tion probabilities of medium DRL patients in the last
6 months of the longer-term SENSE trial (see online
supplementary table B). This was judged an appropriate
approach, with the model conclusion subsequently
found to be insensitive to these data because of the
small incremental proportion of patients between treat-
ments at medium DRL at 12 months (table 8).
To model relapse from the long-term controlled drink-
ing state, we used a similar approach to Barbosa et al,26
with the probability of relapse based on the rates of
patients relapsing from treatment or retaining the same
drinking state in a 10-year study performed by Taylor
et al.27 In Taylor et al the yearly recurrence to heavy
drinking after response was estimated to be 14–19%; in
the current model, we conservatively used 19%.
Incidence of alcohol-attributable diseases, injuries and death
Alcohol-attributable events considered in the model
were categorised based on their pathophysiology of
occurrence with regard to level and pattern of alcohol
consumption (table 5). We implemented these in the
model using risk equations that were developed by the
Canadian Centre for Addiction and Mental Health
(CAMH) using published meta-analyses based on system-
atic literature reviews and were previously used for a
population-based analysis.28
The likelihood of each patient experiencing a harmful
event depended on the level and pattern of alcohol
consumption. The risk of patients experiencing
alcohol-attributable harmful events (both morbidity and
mortality) was calculated as shown in equation 1, where
Population Risk Event(i) is the risk of an event i for a
given time period for the general population (see
online data supplementary table C), and RREvent(i)(x)
is the relative risk of having event i given alcohol con-
sumption of x, as derived from the CAMH risk
equations.
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Equation 1 Risk of experiencing alcohol-attributable
harmful events
Personal Risk Eventði; xÞ ¼ PopulationRisk EventðiÞ
 RREventðiÞðxÞ ð1Þ
We calculated the Personal Risk Event(i,x) in accord-
ance with the level of alcohol consumption. To consider
both the level and pattern of consumption, we used
pooled alcohol consumption data from the ESENSE 1,
ESENSE 2 and SENSE trials to derive mean levels of
alcohol consumption per day, per HDD and the mean
number of HDDs per month for each DRL (table 4).
Depending on the event’s pathophysiology of occur-
rence, the Personal Risk Event(i,x) of experiencing it
depended on either immediate or continuous drinking
level. For events associated with immediate drinking, the
Personal Risk Event(i,x) was determined using the daily
drinking level per HDD and the number of HDDs per
month. Thus, on non-HDDs, the Personal Risk Event(i,
x) was the same as the risk of the event occurring in the
general population. For harmful events as a result of
continuous drinking, we based the Personal Risk Event
(i,x) of experiencing these on average monthly drinking
levels. The resulting relative risks and probabilities used
in the model are presented in online supplementary
tables D–G.
In line with earlier publications, we did not deem it
realistic to assume that a patient would experience a
higher risk of transport-related or other injuries for the
entire day.2 29 To account for this we set the time that
the patient was at risk of experiencing these events to
3 h. This assumption was developed by Taylor et al, who
took into account the number of drinks consumed, the
rapidity of consumption, the rate of liver metabolism
and the time taken to reach a certain blood alcohol con-
centration to identify 3 h as a general assumption for
the time after consuming alcohol during which there is
a signiﬁcantly higher risk of harmful events.30
Utilities
We incorporated utility weights for all drinking health
states and alcohol-attributable harmful events in the
model (table 6). In the three nalmefene clinical trials,
quality of life was measured using EQ-5D at baseline, 3
and 6 months, and additionally at 12 months for SENSE.
For health state utilities in the base-case, we estimated
the mean utility difference between the two treatment
strategies in the short-term phase of the model using the
area between the curves of pooled adjusted mean utility
scores for nalmefene and placebo patients from the
trials at every 3 months from baseline to 1 year (adjusted
for the baseline utility and assuming a linear transition
between the mean utilities at each time point). This
method of applying utilities from a clinical trial was
informed by the NICE Clinical Guideline on alcohol use
disorders and has the advantage of being able to
capture the disutility of adverse events relating to nalme-
fene.31 For the long-term phase of the model, we
derived utility weights for each of the three DRL states
from pooled data from the nalmefene trials (table 6).
Utility weights for drinking health states were subse-
quently varied in a sensitivity analysis.
During the short-term phase of the model, for both
temporary and serious harmful events, patients incurred
event-related utility decrements (and the addition of
event-related costs) applied to the utilities (and costs)
incurred independently by their DRL health states
(table 6). Using the same approach as for the Shefﬁeld
Alcohol Policy Model,19 disutilities were calculated using
the utilities of harmful events proposed in the Shefﬁeld
Alcohol Policy Model (table 6),19 subtracted from the
general population utility (0.852). In the long-term
phase of the model, for temporary and serious harmful
event states, the QALYs (and costs) related to the event
itself were calculated for the patient, using the utility
value from the Shefﬁeld Alcohol Policy Model and cal-
culating a QALY for the time the patient was in that
health state. For temporary events, accumulation of
QALYs from the drinking state was considered, whereas
Table 5 Alcohol-attributable harmful events included in the model
Type Event Effect Modelled as
Continuous-drinking events
Alcohol-attributable diseases associated with
continuous alcohol consumption over time
Lower respiratory infections Temporary Tunnel state*
Haemorrhagic stroke Serious Postevent state†
Cirrhosis of the liver Serious Postevent state
Pancreatitis Serious Postevent state
Immediate-drinking events
Alcohol-attributable diseases or injuries incurred
from a single episode of heavy alcohol consumption
Ischaemic heart disease Serious Postevent state
Ischaemic stroke Serious Postevent state
Transport injuries Temporary Tunnel state
Injuries other than from transport Temporary Tunnel state
*1 month.
†Serious event state; patients could also transition to the death absorbing state from a temporary event, serious event or from general
mortality.
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Table 6 Costs, utilities and resource use inputs to the model for the base-case analysis
Base-case
Parameter Values
DRL health states Utility Source
Short-term DRLs 0.017* ESENSE 1, ESENSE 2, SENSE14 15
Long-term high/very high DRL 0.795 ESENSE 1, ESENSE 2, SENSE14 15
Long-term medium DRL 0.825 ESENSE 1, ESENSE 2, SENSE14 15
Long-term controlled drinking 0.862 ESENSE 1, ESENSE 2, SENSE14 15
Treatment
Proportion
of visits
Number of visits
in first month
Number of subsequent
visits per month Cost Source
Nalmefene, one dose – – – £3.03 MIMS36
Visit to GP including psychosocial
support†
75% 3 1 £53 PSSRU34
First attendance to specialised care
including psychosocial support
25% 3 1 £222 PSSRU34
Follow-up attendance to specialised
care including psychosocial support
3 1 £98 PSSRU34
Alcohol-attributable harmful
events‡ Utility Source
Cost
per event Source
Ischaemic heart disease 0.643 Sheffield Alcohol Policy
Model19
£2407 Sheffield Alcohol Policy Model§19
Ischaemic stroke 0.564 Sheffield Alcohol Policy
Model19
£3949 Sheffield Alcohol Policy Model§19
Haemorrhagic stroke 0.657 Sheffield Alcohol Policy
Model19
£5602 Sheffield Alcohol Policy Model§19
Cirrhosis of the liver 0.494 Sheffield Alcohol Policy
Model19
£3623 Sheffield Alcohol Policy Model§19
Pancreatitis 0.447 Sheffield Alcohol Policy
Model19
£4224 Sheffield Alcohol Policy Model§19
Lower respiratory infections 0.200¶ Sisk et al37 £2999** NHS reference cost database
(2010–2011)33
Motor vehicle accidents 0.598 Sheffield Alcohol Policy
Model19
£5283 Sheffield Alcohol Policy Model§19
Injuries other than from transport 0.592†† Sheffield Alcohol Policy
Model19
£5116 Sheffield Alcohol Policy Model§19
*QALY difference between nalmefene plus psychosocial support and psychosocial support alone for the first year of treatment, calculated
from the clinical trials (‘area between the curves’). QALYs lost were later applied to each arm for the consideration of alcohol-attributable
harmful events. A mixed model repeated measures analysis was carried out using EQ-5D utilities and observed case data from all three trials
to estimate treatment effect for the first 6 months. The model used an unstructured covariance matrix and included country, sex, time (months
1–6) and treatment as fixed effects, as well as baseline value-by-time and treatment-by-time interactions.
†An estimate based on a 17.2 min visit to a general practitioner.
‡Hospital admission data only took into account the first diagnosis for hospitalisation and not the multiple alcohol-attributable conditions that
are often diagnosed and managed during the same hospitalisation.
§Based on ICD-10 code of events, including the following components associated with one hospital admission: inpatient visits, outpatient
visits, accident and emergency visits, ambulance general practitioner consultation, nurse visits and other healthcare costs. For events with
multiple codes, the weighted average calculated from the proportion of admissions reported in the Hospital Episode Statistics (2010–2011) for
England was used.
¶The utility score from Sisk et al37 was during patient hospitalisation. Thus it was applied to the model for 9 days, which was the weighted
average length of hospital stay for lower respiratory infections.33
**Weighted average using Elective Inpatient HRG Data; currency code DZ11A, DZ11B, DZ11C, DZ23A, DZ23B, DZ23C.
††The utility value used in the model for other injuries was calculated as a weighted average combining the utility scores presented in the
‘Sheffield alcohol policy model’ for the subevents included in ‘other injuries’ (based on International Classification of Disease-10 codes) and
these were matched with the number of admissions reported in Hospital Episode Statistics (2010–2011) for England (ICD-10 data used for
modelling the incidence of alcohol-attributable events).19
Source: The utilities used in the Sheffield alcohol policy model were derived from a single source, the Health Outcomes Data Repository
(HODaR) 2008, to avoid potential bias and variability between studies.38 The HODaR data measure utilities using the EQ-5D as
recommended by NICE for health economic evaluations. Data used in the Sheffield alcohol policy model were collected by the Cardiff & Vale
NHS Hospital Trust serving a local population of 424 000 and providing tertiary care for the whole of Wales. Patients discharged from hospital
were requested to complete an EQ-5D questionnaire 6 weeks after their discharge. Data were collected on: demography, health utility (EQ-5D
index) and diagnoses (ICD-10). A mean utility value was extracted for each condition based on diagnoses (or ICD-10 codes) and adjusted for
age using the % increment/decrement observed for utilities in the general population.
DRL, drinking-risk level; GP, general practitioner; NHS, National Health Service; No., number; QALY, quality-adjusted life year.
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for serious events the event QALY was applied without
considering QALYs associated with drinking alcohol.
Resource use and costs
Costs and resource use included in the model were direct
medical costs for the treatment of alcohol dependence
and for the management of alcohol-attributable harmful
events (table 6). The costs for treating alcohol depend-
ence included the cost of the drug and the cost of 20 min
sessions of psychosocial support, the latter of which was
assumed to be provided during medical consultations at
both general and specialist practices (table 6). This is
aligned with experience in the nalmefene clinical trials
and current practice in the UK.11 32 Nalmefene intake
per DRL was calculated by pooling data from the three
clinical trials (table 4). In these trials, nalmefene posol-
ogy was as-needed, in line with its indication.25 We did
not include costs for adverse events associated with nal-
mefene use in the model, as the common adverse events
reported in the three clinical trials were mild (nausea,
headache, dizziness and insomnia) from a clinical per-
spective and were not thought to incur signiﬁcant add-
itional costs.14 15 Costs and resource use associated with
the occurrence of alcohol-attributable harmful events
were based on those used in the Shefﬁeld Alcohol Policy
model with the exception of lower respiratory infections,
which were calculated using the NHS reference cost data-
base (table 6).19 33
We inﬂated costs to 2010/2011 when relevant, using
the Hospital and Community Health Services Index.34
In addition, we discounted all costs and outcomes in the
model at an annual rate of 3.5%, in line with NICE
recommendations.35
Sensitivity analysis
We conducted probabilistic sensitivity analysis (PSA) for
5000 iterations for all parameters in the model estimated
with uncertainty (see online supplementary table H),
using Monte Carlo simulation in Microsoft Excel 2010.39
Parameter uncertainty was deﬁned by probability distri-
butions as recommended by Briggs et al.40 Depending
on the model parameter, we based uncertainty around
the parameter estimates on calculated or reported
patient counts, SEs or range. β and Dirichlet distribu-
tions were used for transition probabilities and utility
weights, γ distributions for costs and normal distribu-
tions for the regression parameters used in calculating
the relative risks of alcohol-attributable harmful events.
The distributions used in the PSA for each parameter
are given in online supplementary table H.
We performed one-way sensitivity analyses (OSA) on
128 parameters to investigate each individual para-
meter’s impact on the cost-effectiveness of nalmefene
(see online supplementary table H). These corre-
sponded to all model parameters except the transition
probabilities between drinking levels and dropout rates,
which we investigated in the PSA. Using an approach
recommended by Briggs et al,41 we based the ranges
tested in the OSA on the statistical uncertainty around
the estimates using their 95% CI. When a 95% CI was
not available for a parameter, we deﬁned a credible
range. For parameters close to the population data, a
range was deﬁned as the 95% CI assuming that the SE
was 10% of the mean value, and for parameters based
on population sample data the 95% CI assuming a SE of
20% of the mean value was used. For other parameters
where statistical uncertainty was not available, we varied
estimates by range of interest within credible values
informed by clinical practice. A list of the parameters
varied in the sensitivity analyses is given in online supple-
mentary table H.
Additionally, we ran the model under a number of
alternative scenarios to investigate the impact of varying:
the time horizon in the model from 5 years through to
1 year; the nalmefene intake from as-needed to every day;
and utility weights for DRL health states using EQ-5D
data from a naturalistic disease management study of
patients with alcohol dependence in the UK primary care
setting at the general practitioner level (STREAM study)
(table 7).42 We also included scenarios to assess the effect
of removing all harmful events from the model.
Quality-control procedures were performed on the
ﬁnal version of the cost-effectiveness model and
included veriﬁcation of all input data with the original
sources, a series of diagnostic tests to conﬁrm that the
model had correctly applied all formulae, and a review
of the model calculations and programming.43
RESULTS
Patient evolution through the 5-year time horizon
During the ﬁrst year of the model, the use of nalmefene
plus psychosocial support considerably reduced the
number of patients in the high and very high DRLs com-
pared with psychosocial support alone, and increased the
number of patients in the low and abstinent DRLs. These
observations are in favour of nalmefene plus psychosocial
support compared to psychosocial support alone, and are
aligned with results from the clinical trials (table 8). After
1 year, these trends continued for the compared treat-
ment arms. This incremental difference in treatment efﬁ-
cacy over the model time horizon can be seen in terms of
the resulting additional alcohol-attributable events in the
psychosocial support arm (table 8).
Table 7 Utility values from the STREAM study used in
scenario sensitivity analyses
DRL health states (entire time
horizon) Utility Source
Very high risk 0.531 STREAM42
High risk 0.609 STREAM42
Medium risk 0.714 STREAM42
Low risk 0.755 STREAM42
Abstinence 0.816 STREAM42
DRL, drinking risk level.
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Incidence of alcohol-attributable harmful events
Nalmefene plus psychosocial support led to fewer
harmful morbidity and mortality events than psychosocial
support alone (table 9), which is in line with the differ-
ences in drinking behaviours observed in the two arms.
After 5 years, nalmefene plus psychosocial support led to
the avoidance of 7179 (95% CI 4244 to 12 654)
alcohol-attributable diseases or injuries and 309 (95% CI
181 to 641) deaths per 100 000 patients versus psycho-
social support alone. The exploratory analysis modelling
the ‘no treatment’ arm demonstrated the important
public health beneﬁt for patients entering treatment for
alcohol dependence: compared with ‘no treatment’, nal-
mefene plus psychosocial support led to the avoidance of
20 202 (95% CI 13 942 to 27 243) alcohol-attributable dis-
eases or injuries and 864 (95% CI 558 to 1469) deaths
per 100 000 patients.
The differences in the incidence of alcohol-
attributable diseases or injuries between the model arms
resulted in cost savings for the English healthcare system
with nalmefene use after 1 and 5 years of treatment initi-
ation (table 10).
Base-case analysis
Taking into consideration the outcomes and costs gener-
ated by the model at the end of the 5-year time horizon,
the base-case analysis concluded that nalmefene in com-
bination with psychosocial support had an incremental
cost-effectiveness ratio (ICER) of £5204 per QALY gained
compared with psychosocial support alone (table 11).
Thus, adding nalmefene to psychosocial support is
expected to be a cost-effective option at a £20 000 per
QALY gained decision threshold, compared with psycho-
social support alone.
The clinical improvement seen with nalmefene plus psy-
chosocial support compared with psychosocial support
alone was reﬂected in the larger gain of QALYs with nalme-
fene plus psychosocial support than with psychosocial
support alone (table 11). An analysis of the costs associated
with the two treatment strategies revealed that the largest
proportion of the costs for both strategies was for medical
visits followed by costs due to harmful events (table 11).
Probabilistic sensitivity analysis
The PSA estimated that there is 94% probability that nal-
mefene plus psychosocial support is cost-effective at a
willingness-to-pay threshold of £20 000 per QALY gained
compared to psychosocial support alone (ﬁgure 2).
Results of the one-way sensitivity analysis
Overall, the analysis concluded that the base-case results
were robust. The parameters with the greatest impact on
the cost-effectiveness results were increasing the number
of medical visits per month (independently, for both treat-
ments) from one to two visits per month, and the utility
values used for the short-term phase (ﬁgure 3). Of all 128
parameters examined in the OSA, the results of the ana-
lysis for the parameters identiﬁed as having the greatest
impact on cost-effectiveness are presented in online sup-
plementary table I. No OSAs altered the conclusion of the
base-case analysis that adding nalmefene to psychosocial
support is a cost-effective opportunity for healthcare
systems in the UK.
Results of the scenario analysis
DRL health state utility values
A scenario analysis using the DRL health state utility values
from the STREAM study resulted in a decrease in the cost
Table 8 Proportions of patients per health state at the end of each year
Very high risk High risk Medium risk Low risk Abstinence Death* Serious events†
Year 1
NMF 0.18 0.17 0.12 0.40 0.10 0.01 0.02
PS 0.26 0.27 0.14 0.22 0.08 0.01 0.02
Very high
risk/high risk
Medium risk Low risk/abstinence
(controlled drinking state)
Death* Serious events†
Year 2
NMF 0.38 0.07 0.50 0.01 0.04
PS 0.56 0.07 0.30 0.02 0.04
Year 3
NMF 0.40 0.04 0.47 0.02 0.06
PS 0.58 0.05 0.28 0.02 0.07
Year 4
NMF 0.42 0.03 0.44 0.03 0.07
PS 0.60 0.03 0.25 0.03 0.09
Year 5
NMF 0.44 0.03 0.40 0.04 0.09
PS 0.60 0.02 0.22 0.04 0.11
*Absorbing state.
†Serious event state (‘post-event state’): Ischaemic heart disease; Haemorrhagic stroke; Ischaemic stroke; Cirrhosis of the liver; Pancreatitis.
NMF, nalmefene plus psychosocial support; PS, psychosocial support alone.
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Table 9 Number of patients experiencing modelled harmful events at one year and five years per 100 000 patients for nalmefene plus psychosocial support, psychosocial
support alone or patients in the ‘no treatment’ arm
Event per 100 000
patients (95% CI)
1 year Difference 5 years Difference
NMF PS No Tx PS-NMF No Tx-NMF NMF PS No Tx PS-NMF No Tx-NMF
Ischaemic heart
disease
1186 (861
to 1732)
1303 (901
to 1995)
1573 (991 to
2526)
117 (39 to
271)
387 (129 to
802)
5834 (4339 to
8526)
6494 (4540 to
9979)
7686 (4841 to
12 202)
660 (200 to
1678)
1852 (528 to
3765)
Ischaemic stroke 269 (199
to 393)
297 (209 to
454)
359 (232 to
580)
28 (9 to 63) 90 (32 to
188)
1348 (998 to
1973)
1514 (1053 to
2361)
1805 (1123 to
2901)
167 (54 to
439)
457 (132 to
959)
Haemorrhagic stroke 105 (90 to
127)
114 (95 to
142)
136 (107 to
179)
9 (4 to 17) 31 (16 to
52)
427 (368 to
534)
477 (401 to
624)
571 (447 to
750)
50 (25 to 99) 143 (75 to
222)
Liver cirrhosis 203 (150
to 287)
244 (175 to
364)
352 (234 to
533)
41 (22 to
83)
148 (83 to
250)
885 (697 to
1260)
1092 (851 to
1623)
1500 (1093 to
2171)
207 (114 to
407)
615 (368 to
932)
Pancreatitis 229 (156
to 365)
288 (190 to
486)
451 (274 to
766)
59 (28 to
130)
222 (115 to
408)
778 (610 to
1169)
960 (735 to
1524)
1358 (961 to
2135)
182 (91 to
394)
580 (336 to
986)
Lower respiratory tract
infections
918 (687
to 700)
968 (689 to
706)
1109 (713 to
732)
50 (−3 to
10)
192 (23 to
34)
2917 (2627 to
2903)
3256 (2882 to
3266)
3843 (3319 to
3551)
339 (135 to
496)
926 (543 to
809)
Transport injuries 548 (524
to 590)
720 (681 to
778)
1109 (1097
to 1119)
172 (124 to
224)
560 (518 to
584)
2515 (2333 to
2980)
3505 (3248 to
4166)
5318 (5070 to
5488)
990 (619 to
1513)
2803 (2309 to
2979)
Injuries other than
transport
3091
(1870 to
5174)
3911 (2336
to 6566)
5734 (3339
to 9596)
820 (418 to
1486)
2643 (1457
to 4460)
13 657(9089
to 22 419)
18 241
(12 125 to
30 474)
26 483
(16 680 to
41 824)
4584 (2411
to 9126)
12 826 (7107
to 20 140)
Deaths from serious
events
260 (200
to 442)
348 (255 to
621)
493 (332 to
939)
88 (52 to
192)
233 (131 to
503)
1273 (1021 to
2013)
1491 (1171 to
2461)
1892 (1393 to
3216)
219 (117 to
518)
620 (348 to
1226)
Deaths from
short-term events
185 (170
to 215)
225 (203 to
266)
270 (237 to
324)
41 (29 to
53)
86 (65 to
110)
1013 (931 to
1149)
1103 (1010 to
1279)
1257 (1122 to
1458)
90 (51 to
162)
245 (161 to
339)
Total number of
events
6549
(5074 to
8524)
7845 (5962
to 10 381)
10 823(7962
to 14 489)
1296 (788
to 2004)
4273 (2842
to 5950)
28 361
(23 817 to
38 177)
35 540
(29 699 to
49 069)
48 563
(38 527 to
64 212)
7179 (4244
to 12 654)
20 202
(13 942 to
27 243)
Total number of
deaths
445 (384
to 628)
573 (479 to
853)
763 (599 to
1212)
129 (87 to
235)
319 (212 to
585)
2285 (2021 to
3027)
2594 (2273 to
3595)
3149 (2634 to
4466)
309 (181 to
641)
864 (558 to
1469)
NMF, nalmefene plus psychosocial support; No Tx, ‘No treatment’ arm; PS, psychosocial support alone.
Table 10 Number and cost of alcohol-attributable harmful events avoided between the model arms
One year Five years
PS-NMF No Tx-NMF PS-NMF No Tx-NMF
Difference in number of events per
100 000 patients (95% CI)
1296 (788 to 2004) 4273 (2842 to 5950) 7179 (4244 to 12 654) 20 202 (13 942 to 27 243)
Cost difference* per 100 000 patients
(95% CI)
£5 900 000 (£3 200 000 to
£10 100 000)
£19 300 000 (£11 600 000 to
(£30 400 000)
£29 900 000 (£16 200 000 to
£58 200 000)
£84 500 000 (£51 200 000 to
£128 000 000)
Cost difference* per patient (95% CI) £59 (£32 to £101) £193 (£116 to £304) £299 (£162 to £582) £845 (£512 to £1280)
*Differences in costs are those incurred as a result of differences in harmful events only.
NMF, nalmefene plus psychosocial support; No Tx, ‘No treatment’ arm; PS, psychosocial support alone.
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per QALY gained to £1990 with 100% probability of cost-
effectiveness at the £20 000 threshold (see online supple-
mentary table J). This is expected, given the higher incre-
mental variation between the DRL utility scores from this
naturalistic study compared to those from the nalmefene
clinical trials, where the patient inclusion and exclusion
criteria pertaining to any randomised controlled trial
would have reduced the variation in impact of interven-
tions on patients’ quality of life (table 6).
Time horizon
The model was sensitive to the time horizon, resulting
in a cost per QALY gained of £24 412 and 35% probabil-
ity of cost-effectiveness at the £20 000 threshold when a
1-year time horizon was used (see online supplementary
table J). When considering the scenarios using 2-year,
3-year and 4-year time horizons, it becomes clear that
the cumulative effect of incremental QALYs drives the
improvement in cost-effectiveness results with increased
time horizon (see online supplementary tables J and K).
This incremental increase in QALY gain each year of the
model time horizon is a result of the superior effective-
ness for the nalmefene arm gained during the ﬁrst
12 months. During this phase, patients in the nalmefene
arm exhibited reduced alcohol consumption compared
to those in the psychosocial support arm, thus when the
long-term phase of the model began there was a higher
proportion of patients in the controlled drinking state
and a lower proportion of patients in the high/very high
DRL health state for nalmefene plus psychosocial
support than for psychosocial support alone. With the
exception of the medium DRL health state (see online
supplementary table B), no additional difference in
treatment beneﬁt between the arms was considered
beyond the retained differences in proportions of
patients in the different health states after the ﬁrst
12 months. Although treatment-speciﬁc transition prob-
abilities were used for the long-term medium DRL
health state, the model results were insensitive to this
feature when tested in an extreme scenario against nal-
mefene where all patients in the medium DRL health
state at the end of 12 months transitioned to the high
and very high DRL state if they were in the nalmefene
arm, or to the controlled drinking state if they were in
the comparator arm. An analysis using the STREAM
utility values plus a 1-year time horizon proved cost-
effective, showing an ICER of £13 364 with 89% prob-
ability of cost-effectiveness at the £20 000 threshold.
Nalmefene intake
In the scenario investigating nalmefene intake, the use of
nalmefene daily as opposed to on an as-needed basis
resulted in a cost per QALY of £10 080 with 84% probabil-
ity of being cost-effective at the £20 000 threshold. It
should be noted that this scenario is not representative of
real-life patterns of nalmefene intake, where nalmefene
dose correlated with the level of alcohol consumption, as
observed in the nalmefene clinical trials (table 5).14
Table 11 Incremental cost, QALY, life year, cost per life year and cost per QALY for nalmefene plus psychosocial support
versus psychosocial support alone (base-case results at 5 years)
Mean per patient (95% CI)
Nalmefene plus
psychosocial support Psychosocial support
Nalmefene plus psychosocial
support vs psychosocial support
Total cost per patient £2889 (£2557 to £3777) £2454 (£2085 to £3436) £434 (£197 to £675)
Medical visits for AD treatment
(including psychosocial support)
£1187 (£1007 to £1822) £1060 (£868 to £1567) £127 (£43 to £359)
Cost of nalmefene drug
treatment
£605 (£522 to £666) n/a £605 (£522 to £666)
Cost of harmful events £1096 (£804 to £1657) £1395 (£1009 to £2192) −£299 (−£162 to −£582)
Life years per patient 4.42 (4.40 to 4.43) 4.41 (4.38 to 4.42) 0.01 (0.01 to 0.02)
QALYs per patient 3.57 (3.46 to 3.60) 3.48 (3.40 to 3.52) 0.08 (0.01 to 0.13)
Cost per life year n/a n/a £49 174
Cost per QALY n/a n/a £5204
All costs and outcomes in the model were discounted at an annual rate of 3.5%, in line with NICE recommendations,35 and costs were inflated
to 2010/2011 when relevant using the Hospital and Community Health Services Index.34
AD, alcohol dependence; QALYs, quality-adjusted life years.
Figure 2 Cost-effectiveness acceptability curve for nalmefene
plus psychosocial support versus psychosocial support alone
(base-case results at 5 years). Sims: simulations.
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Harmful events
A scenario where all harmful events were removed from
the model at a 1-year time horizon resulted in a cost per
QALY of £29 142 with 24% probability of cost-
effectiveness at a £20 000 threshold. This suggests a
negligible effect of including these events on the cost-
effectiveness results at 1 year. Conversely, excluding
these events across a 5-year time horizon caused a more
noticeable impact on incremental costs and QALYs com-
pared to the base-case analysis, producing an ICER of
£11 530 and 70% probability of cost-effectiveness at a
£20 000 threshold.
DISCUSSION
The objective of this economic analysis was to assess the
cost-effectiveness of nalmefene plus psychosocial
support versus psychosocial support alone for the treat-
ment of nalmefene’s licensed population (patients with
high/very high DRLs at initial assessment and 2 weeks
later). In addition, the analysis aimed to demonstrate
the public health beneﬁt of reducing alcohol consump-
tion and the value for the healthcare system of patients
entering treatment for alcohol dependence. From the
base-case cost-effectiveness assessment, nalmefene had
an ICER of £5204 per QALY gained. As the NICE
willingness-to-pay threshold is stated to be £20 000–
£30 000 per QALY gained, with treatments demonstrat-
ing innovation and a high degree of certainty around
the ICER being considered at the higher end of this
range, nalmefene plus psychosocial support appears to
be a cost-effective strategy versus psychosocial support
alone.44 All parameters with statistical uncertainty,
including the transition probabilities between drinking
levels and dropouts, were varied in the PSA and demon-
strated the robustness of the results to this uncertainty.
In the OSA, the parameter with the largest impact on
cost-effectiveness was increasing the number of medical
visits per month in the nalmefene arm from one to two.
However, for all analyses the ICER remained below
NICE’s willingness-to-pay threshold, and nalmefene plus
psychosocial support remained a cost-effective strategy.
Nalmefene plus psychosocial support led to the avoid-
ance of 7179 alcohol-attributable diseases or injuries and
309 deaths per 100 000 patients versus psychosocial
support alone at 5 years, which represents a considerable
beneﬁt. The number of avoided harmful events esti-
mated from this model is likely to be an underestimation
of the number of events avoided in real life for several
reasons. First, the model used hospital admission data
that took into account only the ﬁrst diagnosis for hospi-
talisation, while alcohol-dependent patients often have
multiple alcohol-attributable conditions diagnosed and
managed during the same hospitalisation. It was also
assumed that patients can have only one serious event at
a time, ignoring the non-negligible possibility of
comorbidities. Additionally, when modelling the short-
term events it was assumed that patients did not have an
additional risk of experiencing these events compared
with the general population on days that were not a
HDD, suggesting there could be an even larger public
health beneﬁt of nalmefene for the treatment of alcohol
dependence than that reported in this analysis.
A comparison of the number of alcohol-attributable
harmful events avoided with nalmefene plus psycho-
social support versus ‘no treatment’ indicated that there
Figure 3 Tornado diagram of the 15 most sensitive parameters in the model (base-case results at 5 years). GP, general practitioner;
ICER, incremental cost-effectiveness ratio; PS, psychosocial support; QALY, quality-adjusted life year; RR, relative risk.
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would be a saving per patient of £193 (95% CI 116 to
304) over 1 year and £845 (95% CI 512 to 1280) over
5 years as a result of these events not occurring (table
10). While nalmefene plus psychosocial support clearly
results in a reduction in harmful events compared to no
treatment, this was an exploratory analysis to allow a
crude estimation of the likely public health beneﬁt of
patients being treated for alcohol dependence. As such,
the analysis assumed that patients in the ‘no treatment’
arm remained in a high or very high DRL for the entire
time horizon, and did not take into account the possibil-
ity that these patients could reduce their level of alcohol
consumption without receiving treatment. The number
of harmful events occurring with no treatment may
therefore have been overestimated. The reduction in
number of harmful events with nalmefene plus psycho-
social support compared to no treatment appears to be
mostly due to the provision of psychosocial support
(table 10); however, this observation may be due to over-
estimation of the number of harmful events occurring
with ‘no treatment’ compared to the other treatment
arms. As stated previously, the comparison with a ‘no
treatment’ arm was intended as an exploratory analysis
and psychosocial support should be considered a more
relevant comparator to nalmefene than ‘no treatment’,
in alignment with current practice in the UK.8 Finally,
even if nalmefene treatment is more costly than psycho-
social support alone, we have clearly shown it to be a
cost-effective option because of the additional gain in
clinical beneﬁt from the drug.
This cost-effectiveness analysis used an innovative
approach towards modelling the treatment of alcohol
dependence. The model incorporated DRL categories
as deﬁned by the WHO and abstinence as main health
states, which is a method more sensitive to changes in
alcohol consumption than previous models based on
the success or failure of treatment. The latter approach
was used in developing the NICE clinical guidelines for
the treatment of alcohol dependence, whereby NICE
explored the relative cost-effectiveness of pharmaco-
logical treatments used as ﬁrst-line treatment for main-
taining abstinence in patients with alcohol dependence
using two health states related to success and failure.8
Our approach of using health states for DRLs and
abstinence was developed to model the novel use of
pharmacological treatment as a ﬁrst-line option for redu-
cing alcohol consumption in patients with alcohol
dependence. This represents a main strength of the
present study. A further strength of this analysis was the
use of observed patient-level data for modelling multiple
health states and, where assumptions were needed, the
most conservative option was selected to avoid biasing
the model results. Conservative population incidence
data and costs were used when modelling
alcohol-attributable harmful events, as previously
described.
A 5-year time horizon was chosen to evaluate the cost-
effectiveness of nalmefene plus psychosocial support
versus psychosocial support alone on the basis that this
would be sufﬁcient to capture the longer-term conse-
quences of alcohol dependence, while limiting uncer-
tainty from extrapolating data from the current
literature. To consider the impact of this decision, a
number of scenario analyses were conducted with differ-
ent time horizons (see online supplementary table J). In
the scenario using base-case utilities over a 1-year time
horizon, nalmefene plus psychosocial support had a low
probability (35%) of being cost-effective compared to
psychosocial support alone at a £20 000 per QALY deci-
sion threshold (although there was an 89% probability
of cost-effectiveness over a 1-year time horizon in a scen-
ario using utilities from the real-world STREAM study).
On the other hand, scenarios using a time horizon of
2 years or more had more than 75% probability of being
cost-effective at this threshold (see online supplementary
table J). This difference was mainly driven by the incre-
mental QALYs accrued after each year in the model (see
online supplementary table K). For conservative model-
ling, the incremental effectiveness between the two treat-
ment arms gained during the ﬁrst 12 months was
retained for the remainder of the model time horizon,
represented by the difference at 12 months in the
number of patients who had responded to treatment
between the compared arms. However, with the excep-
tion of the medium DRL health state, no additional dif-
ferential effect per se between the treatment arms was
considered to arise after 12 months. For the medium
DRL health state, transition probabilities were extrapo-
lated from the ﬁrst year of the model and therefore dif-
fered between treatment arms (see online
supplementary table B). Nevertheless, only a small pro-
portion of patients were in this health state for either
treatment arm after the ﬁrst year, and testing this
assumption with an extreme scenario that was unfavour-
able to nalmefene indicated that the model results were
insensitive to this model feature.
For costs, there was a relatively low additional incre-
mental cost from years 2–5, mostly as a result of only
19% of patients returning to treatment each year during
this part of the model (from both arms), while the cost
of hospitalisation as a result of harmful events remained
relatively negligible throughout the model. It is import-
ant to note that a 1-year time horizon is not aligned with
the NICE reference case regarding the use of an appro-
priate model time horizon, as alcohol dependence is a
chronic disease and 1 year would not be long enough to
capture all important differences in costs and outcomes
between the interventions being compared.44 The rele-
vance of considering the long-term consequences of
harmful events is further illustrated by the scenario ana-
lyses excluding these events (see online supplementary
table J); and by the breakdown of cost and QALYs per
year per health state categories (see online supplemen-
tary table K), where these alcohol-attributable harmful
events produced an increasingly more noticeable effect
on incremental QALYs and costs from 1 to 5 years.
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The nalmefene clinical trials were multinational
studies and their use as sources of effectiveness of nal-
mefene in a UK population may therefore be subopti-
mal. Nevertheless, the SENSE study included patients
from the UK, and these trials are likely to be somewhat
generalisable to the UK population given that they cap-
tured data on different drinking patterns and cultures
across Europe. A comparison of patient baseline
characteristics in the nalmefene trials to the UK Alcohol
Treatment Trial (UKATT),45 46 in which almost half of
patients opted for alcohol reduction as their treatment
approach, suggests that patients were reasonably compar-
able in terms of age, sex, ethnicity, level of alcohol con-
sumption at study baseline and level of unemployment.
NICE clinical guidelines recommend screening and
brief intervention delivered by a non-specialist practi-
tioner as a cost-effective approach for managing hazard-
ous and harmful drinkers.9 While it could be argued
that BRENDA, as used during the nalmefene clinical
trials, is not representative of best recommended prac-
tice in the UK according to NICE clinical guideline 115
(which recommends cognitive behavioural therapies,
behavioural therapies or social network and
environment-based therapies as ﬁrst-line treatment for
mild alcohol dependence, aligned with the licensed
population for nalmefene),8 9 BRENDA was deemed by
clinical experts to be sufﬁciently similar to ‘extended
brief psychosocial intervention’, the type of psychosocial
intervention used most frequently for patients assessed
in standard UK practice, which supports its validity as
the main comparator to nalmefene in this model.32
Furthermore, a reduction in alcohol consumption was
observed with the BRENDA plus placebo arm in the nal-
mefene trials, therefore it does appear to be effective as
psychosocial intervention for mild alcohol-dependent
harmful drinkers.14 15
The quality of life measures used in the nalmefene
clinical trials, from which the drinking health state util-
ities were derived, were EQ-5D data as recommended by
NICE for use in cost-effectiveness assessment.44 However,
a systematic review of quality of life instruments in ran-
domised controlled trials for alcohol dependence
reported that EQ-5D may not be highly sensitive to
outcome changes in alcohol dependence.47 There could
therefore be insufﬁcient correlation between changes in
drinking behaviour and alcohol consumption with
patient-perceived impact on health status using this
measure, which could have led to an underestimation of
the QALY gains for nalmefene in this analysis. Utilities
from the STREAM study may provide a more realistic
QALY assessment than those from the nalmefene clin-
ical trials given that this was a real-world study, whereas
the exclusion criteria used in the nalmefene trials could
mean that the patients included in these studies were
not representative of real life. When considering the
scenarios that used utility values from the arguably more
realistic STREAM study at 1-year or 5-year time horizons,
the incremental QALYs in both cases were higher.
The study was limited by the fact that we considered
only direct medical costs of treatment and not the wider
impact of alcohol dependence on the population. In
addition, we modelled only a limited number of
alcohol-attributable harmful events due to limitations in
available evidence and the restricted model time
horizon. It is likely that further costs to the healthcare
system or the patient’s quality of life from
alcohol-attributable harmful events were not captured by
the model. Furthermore, we did not consider ongoing
costs beyond the actual acute occurrence of an
alcohol-attributable harmful event in the model. For a
more comprehensive analysis of the cost-effectiveness of
nalmefene, the current model could be extended to
include a societal perspective. An extension of the
present analysis is currently being conducted with a
similar approach to that used in the Shefﬁeld Alcohol
Policy Model to estimate the cost of productivity losses
to society. This model took into account absence from
work and unemployment, as well as the impact of
alcohol consumption on the criminal justice system.19
Finally, while a subpopulation of alcohol-dependent
patients from the nalmefene clinical trials with high/
very high DRLs was considered in the model, it is often
difﬁcult to assess a patient’s DRL in clinical practice. In
order to optimise the cost-effectiveness of nalmefene
plus psychosocial support in clinical practice, appropri-
ate measures to identify patients most suitable for nalme-
fene (patients with high or very high DRL at initial
assessment and 2 weeks later as per nalmefene’s indica-
tion11) are required.
A number of assumptions were made to simplify the
model, which could be considered additional limita-
tions. When patients withdrew from or failed treatment,
we assumed that they would drink continuously at a
high or very high DRL for the remaining model time
horizon, instead of providing the opportunity for these
patients to enter another treatment option. This assump-
tion is, however, likely to have underestimated the
cost-effectiveness of nalmefene, considering the higher
proportion of patients who responded to treatment for
nalmefene plus psychosocial support compared to the
proportion of patients who responded to psychosocial
support alone. Using an approach proposed by Barbosa
et al we also assumed that patients entering the con-
trolled drinking state remained there or relapsed to the
high/very high DRLs, without having the possibility of
entering the medium DRLs. This was to simplify extrapo-
lation of the within-trial model and was based on data
availability. However, as demonstrated in the scenario
analyses, the model cost-effectiveness results are driven
mainly by the differential effects at year one in the
model and reﬁning the long-term phase of the model is
not expected to affect the cost-effectiveness conclusions.
NICE recommends that for patients with
moderate-to-severe alcohol dependence, treatment
should involve medically-assisted alcohol withdrawal fol-
lowed by psychosocial therapy in combination with
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pharmacological treatment to promote maintained
abstinence.8 9 In 2011, NICE published a comparison of
two such pharmacotherapies, naltrexone and acampro-
sate, in terms of relapse rates to heavy drinking after
1 year of treatment in abstinent patients aiming to main-
tain abstinence.8 Mean rates of relapse (82.53% for nal-
trexone; 81.76% for acamprosate) and the uncertainty
around the mean rates remained high with treatment.
This highlights a potential unmet need in the treatment
of alcohol dependence. Nalmefene represents a novel
method for treating alcohol dependence by aiming for
‘harm reduction’ through a reduction in alcohol con-
sumption in non-abstinent patients as opposed to com-
pletely abstaining from alcohol. Besides the immediate
impact of reducing alcohol consumption, the potential
to use nalmefene to prevent patients advancing to more
severe alcohol dependence could, in the long-term, lead
to a further reduction in alcohol-attributable harmful
events and the associated costs. It could also be used to
target a previously undertreated population of alcohol-
dependent patients by providing an alternative treat-
ment strategy for those who are reluctant to accept
abstinence as the treatment goal.
CONCLUSION
In conclusion, results from this cost-effectiveness model
comparing nalmefene plus psychosocial support with
psychosocial support alone demonstrate nalmefene to
be a cost-effective solution for treating alcohol depend-
ence in patients with high/very high DRLs at the
£20 000 per QALY gained willingness-to-pay threshold.
The results also demonstrate considerable public health
beneﬁts of reducing alcohol-attributable harmful events
through the use of nalmefene with psychosocial support.
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